IDEAYA Biosciences, Inc.: management transactions · United States · SEC (Form 4)

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker IDYA, with headquarters in South San Francisco, California, United States. Founded in June 2015, IDEAYA is a precision oncology company focused on the discovery and development of targeted therapeutics for patient populations selected through molecular diagnostics. For French, Belgian and Swiss investors, the company fits the profile of a clinical-stage biotech: high R&D intensity, no mature commercial franchise yet, but meaningful optionality from a diversified pipeline and potentially differentiated scientific positioning. The company’s strategy is centered on biomarker-driven oncology, where patient selection and target biology can create a competitive edge versus broader, less selective cancer approaches. IDEAYA’s lead asset is darovasertib, a PKC inhibitor being developed primarily in uveal melanoma, a rare and serious eye cancer with significant unmet medical need. The program is especially important because it has moved into advanced clinical development, including pivotal studies, and has become the company’s main value driver. Beyond darovasertib, IDEAYA is advancing multiple programs across oncology mechanisms, including DNA damage response, synthetic lethality, ADC-based approaches and other targeted assets in clinical and preclinical stages. In practical terms, IDEAYA is building a portfolio intended to balance near-term clinical catalysts with longer-term pipeline breadth. The company’s competitive position rests on several pillars: precision-medicine expertise, a concentration on genomically or biomarker-selected tumor subsets, and the ability to progress several programs in parallel. It also seeks to capture value through collaborations while retaining commercial rights where possible. This makes IDEAYA more than a single-asset story, although darovasertib remains the central investment thesis. The company’s business model is still largely development-led rather than sales-led, so valuation is likely to remain highly sensitive to clinical readouts, regulatory milestones and partnering decisions. Recent company updates underscore that point. In early 2026, IDEAYA reported full enrollment in its pivotal OptimUM-02 Phase 2/3 trial of darovasertib in combination with crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, and it highlighted progress across other pipeline programs such as IDE034, IDE574 and IDE892. The company also reported approximately $1.05 billion in cash, cash equivalents and marketable securities as of December 31, 2025, which it expects to fund operations into 2030. For investors, that liquidity is important: it reduces financing risk and supports execution, while the ultimate investment case still depends on clinical success and regulatory progress. IDEAYA Biosciences remains a high-quality, science-driven oncology platform with meaningful upside, but also the inherent binary risks of late-stage biotech development.